APA

Jain A. P., Patel K., Pinto S., Radhakrishnan A., Nanjappa V., Kumar M., Raja R., Patil A. H., Kumari A., Manoharan M., Karunakaran C., Murugan S., Keshava Prasad T. S., Chang X., Mathur P. P., Kumar P., Gupta R., Gupta R., Khanna-Gupta A., Sidransky D., Chatterjee A. & Gowda H. (20201106). MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma. : Scientific reports.

Chicago

Jain Ankit P, Patel Krishna, Pinto Sneha, Radhakrishnan Aneesha, Nanjappa Vishalakshi, Kumar Manish, Raja Remya, Patil Arun H, Kumari Anjali, Manoharan Malini, Karunakaran Coral, Murugan Saktivel, Keshava Prasad T S, Chang Xiaofei, Mathur Premendu Prakash, Kumar Prashant, Gupta Ravi, Gupta Rohit, Khanna-Gupta Arati, Sidransky David, Chatterjee Aditi and Gowda Harsha. 20201106. MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma. : Scientific reports.

Harvard

Jain A. P., Patel K., Pinto S., Radhakrishnan A., Nanjappa V., Kumar M., Raja R., Patil A. H., Kumari A., Manoharan M., Karunakaran C., Murugan S., Keshava Prasad T. S., Chang X., Mathur P. P., Kumar P., Gupta R., Gupta R., Khanna-Gupta A., Sidransky D., Chatterjee A. and Gowda H. (20201106). MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma. : Scientific reports.

MLA

Jain Ankit P, Patel Krishna, Pinto Sneha, Radhakrishnan Aneesha, Nanjappa Vishalakshi, Kumar Manish, Raja Remya, Patil Arun H, Kumari Anjali, Manoharan Malini, Karunakaran Coral, Murugan Saktivel, Keshava Prasad T S, Chang Xiaofei, Mathur Premendu Prakash, Kumar Prashant, Gupta Ravi, Gupta Rohit, Khanna-Gupta Arati, Sidransky David, Chatterjee Aditi and Gowda Harsha. MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma. : Scientific reports. 20201106.